Seminars in Oncology
Volume 33 , Pages 10-13 , December 2006

Adjuvant Therapy for Pancreatic Cancer: Current Status, Future Directions

  • William F. Regine

      Affiliations

    • Department of Radiation Oncology, University of Maryland Medical Center, Baltimore MD
    • Corresponding Author InformationAddress reprint requests to William F. Regine, MD, University of Maryland, Department of Radiation Oncology, 22 S. Greene St, Room GGK 0101, Baltimore, MD 21201
    • ,
  • Ross A. Abrams

      Affiliations

    • Department of Radiation Oncology, Rush University Medical Center, Chicago, IL

References 

  1. Yeo CJ, Cameron JL, Sohn TA, et al. Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: Pathology, complications, and outcomes. Ann Surg. 1997;226:248–257
  2. Tepper J, Nardi G, Suit H. Carcinoma of the pancreas: review of MGH experience from 1963–1973—Analysis of surgical failure and its implications for radiation therapy. Cancer. 1976;37:1519–1524
  3. Griffin JF, Smalley SR, Jewell W, et al. Patterns of failure after curative resection of pancreatic carcinoma. Cancer. 1990;66:56–61
  4. Yeo CJ, Abrams RA, Grochow LB, et al. Pancreaticoduodenectomy for pancreatic adenocarcinoma: Postoperative adjuvant chemoradiation improves survival: A prospective, single institution experience. Ann Surg. 1997;225:621–636
  5. Abrams RA. Radiotherapy in the adjuvant management of pancreatic adenocarcinoma. Semin Oncol. 2005;32(suppl 9):S30–S32
  6. Kalser MH, Ellenberg SS. Pancreatic cancer (Adjuvant combined radiation and chemotherapy following curative resection). Arch Surg. 1985;120:899–903
  7. Klinkenbijl JH, Jeekel J, Sahmoud T, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: Phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg. 1999;230:776–782
  8. Garofalo MC, Regine WF, Tan MT. On statistical reanalysis, the EORTC trial is a positive trial for adjuvant chemoradiation in pancreatic cancer. Ann Surg. 2006;244:332–333
  9. Neoptolemos JP, Dunn JA, Stocken DD, et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: A randomised controlled trial. Lancet. 2001;358:1576–1585
  10. Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350:1200–1210
  11. Bakkevold KE, Amesjo B, Dahl O, et al. Adjuvant combination chemotherapy (AMF) following radical resection of carcinoma of the pancreas and papilla of vater–Results of a controlled, prospective, randomized multicenter study. Eur J Cancer. 1993;29A:698–703
  12. Abrams RA, Yeo CJ. Combined modality adjuvant therapy for resected periampullary pancreatic and nonpancreatic adenocarcinoma: A review of studies and experience at the Johns Hopkins Hospital, 1991-2003. Surg Oncol Clin N Am. 2004;13:621–638
  13. Abrams RA, Lillemoe KD, Piantadosi S. Continuing controversy over adjuvant therapy of pancreatic cancer. Lancet. 2001;358:1565–1566
  14. Burris HA, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol. 1997;15:2403–2413
  15. Regine WF, Winter KW, Abrams R, et al. RTOG 9704 a phase III study of adjuvant pre and post chemoradiation (chemoradiotherapy) 5-FU vs. gemcitabine (G) for resected pancreatic adenocarcinoma. J Clin Oncol. 2006;24(suppl):18s;(abstr)

PII: S0093-7754(06)00382-4

doi: 10.1053/j.seminoncol.2006.10.005

Seminars in Oncology
Volume 33 , Pages 10-13 , December 2006

Article Tools

* Image Usage & Resolution